SCOPUS 정보 검색 플랫폼 - 논문 보기

메뉴 건너뛰기

Molecular and Cellular Oncology

Volumn 4, Issue 1, 2017, Pages

Mutant p53–Nrf2 axis regulates the proteasome machinery in cancer

(3) Lisek, Kamil a Walerych, Dawid a Del Sal, Giannino a,b

a Laboratorio Nazionale CIB (Italy)

b UNIVERSITY OF TRIESTE (Italy)

Author keywords

APR 246; cancer; Chip seq; Keap1; multi omics; mutant p53; Nrf2; proteasome; proteomics; TNBC; transcriptomics

Indexed keywords

EID: 85041963321 PISSN: None EISSN: 23723556 Source Type: Journal
DOI: 10.1080/23723556.2016.1217967 Document Type: Article

Times cited : (15)

References (10)

1
- 84954556659
- Mutant p53: One, no one, and one hundred thousand
- PMID:26734571;
- Walerych D, Lisek K, Sal DG. Mutant p53: One, no one, and one hundred thousand. Front Oncol 2015; 5:289; PMID:26734571; http://dx.doi.org/10.3389/fonc.2015.00289
- (2015) Front Oncol , vol.5 , pp. 289
- Walerych, D.¹ Lisek, K.² Sal, D.G.³

2
- 84876976694
- Targeting triple negative breast cancer: Is p53 the answer?
- 23321033,; PMID:,;
- Turner N, Moretti E, Siclari O, Migliaccio I, Santarpia L, D'Incalci M, Piccolo S, Veronesi A, Zambelli A, Del Sal G. Targeting triple negative breast cancer: Is p53 the answer? Cancer Treat Rev 2013; 39:541-50; PMID:23321033; http://dx.doi.org/10.1016/j.ctrv.2012.12.001
- (2013) Cancer Treat Rev , vol.39 , pp. 541-550
- Turner, N.¹ Moretti, E.² Siclari, O.³ Migliaccio, I.⁴ Santarpia, L.⁵ D'Incalci, M.⁶ Piccolo, S.⁷ Veronesi, A.⁸ Zambelli, A.⁹ Del Sal, G.¹⁰

3
- 84976331500
- 27347849, et al.,; PMID:,;
- Walerych D, Lisek K, Sommaggio R, Piazza S, Ciani Y, Dalla E, Rajkowska K, Gaweda-Walerych K, Ingallina E, Tonelli C, et al. Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. 2016; 18:897-909; PMID:27347849; http://dx.doi.org/10.1038/ncb3380
- (2016) Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer , vol.18 , pp. 897-909
- Walerych, D.¹ Lisek, K.² Sommaggio, R.³ Piazza, S.⁴ Ciani, Y.⁵ Dalla, E.⁶ Rajkowska, K.⁷ Gaweda-Walerych, K.⁸ Ingallina, E.⁹ Tonelli, C.¹⁰

4
- 84961390703
- Mutant p53 inhibits miRNA biogenesis by interfering with the microprocessor complex
- 26996669, et al.,; PMID:,;
- Garibaldi F, Falcone E, Trisciuoglio D, Colombo T, Lisek K, Walerych D, Del Sal G, Paci P, Bossi G, Piaggio G, et al. Mutant p53 inhibits miRNA biogenesis by interfering with the microprocessor complex. Oncogene 2016; 35:3760-70; PMID:26996669; http://dx.doi.org/10.1038/onc.2016.51
- (2016) Oncogene , vol.35 , pp. 3760-3770
- Garibaldi, F.¹ Falcone, E.² Trisciuoglio, D.³ Colombo, T.⁴ Lisek, K.⁵ Walerych, D.⁶ Del Sal, G.⁷ Paci, P.⁸ Bossi, G.⁹ Piaggio, G.¹⁰

5
- 84976444942
- The dual roles of NRF2 in cancer
- PMID:27263465;
- Menegon S, Columbano A, Giordano S. The dual roles of NRF2 in cancer. Trends Mol Med 2016; xx:1-16; PMID:27263465; http://dx.doi.org/10.1016/j.molmed.2016.05.002
- (2016) Trends Mol Med , vol.20 , pp. 1-16
- Menegon, S.¹ Columbano, A.² Giordano, S.³

6
- 79960060305
- Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
- et al.,; PMID:21734707;
- DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2012; 475:106-9; PMID:21734707; http://dx.doi.org/10.1038/nature10189
- (2012) Nature , vol.475 , pp. 106-109
- DeNicola, G.M.¹ Karreth, F.A.² Humpton, T.J.³ Gopinathan, A.⁴ Wei, C.⁵ Frese, K.⁶ Mangal, D.⁷ Yu, K.H.⁸ Yeo, C.J.⁹ Calhoun, E.S.¹⁰

7
- 84897421970
- The Nrf2 regulatory network provides an interface between redox and intermediary metabolism
- 24647116,; PMID:,;
- Hayes JD, Dinkova-Kostova AT. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci 2014; 39:199-218; PMID:24647116; http://dx.doi.org/10.1016/j.tibs.2014.02.002
- (2014) Trends Biochem Sci , vol.39 , pp. 199-218
- Hayes, J.D.¹ Dinkova-Kostova, A.T.²

8
- 84889575198
- Modulation of oxidative stress as an anticancer strategy
- 24287781,; PMID:,;
- Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 2013; 12:931-47; PMID:24287781; http://dx.doi.org/10.1038/nrd4002
- (2013) Nat Rev Drug Discov , vol.12 , pp. 931-947
- Gorrini, C.¹ Harris, I.S.² Mak, T.W.³

9
- 84873532942
- Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species
- 22899716, et al.,; PMID:,;
- Kalo E, Kogan-Sakin I, Solomon H, Bar-Nathan E, Shay M, Shetzer Y, Dekel E, Goldfinger N, Buganim Y, Stambolsky P, et al. Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species. J Cell Sci 2012; 125:5578-86; PMID:22899716; http://dx.doi.org/10.1242/jcs.106815
- (2012) J Cell Sci , vol.125 , pp. 5578-5586
- Kalo, E.¹ Kogan-Sakin, I.² Solomon, H.³ Bar-Nathan, E.⁴ Shay, M.⁵ Shetzer, Y.⁶ Dekel, E.⁷ Goldfinger, N.⁸ Buganim, Y.⁹ Stambolsky, P.¹⁰

10
- 84964446349
- Targeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy
- 26870698,; PMID:,;
- Bykov VJN, Zhang Q, Zhang M, Ceder S, Abrahmsen L, Wiman KG. Targeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy. Front Oncol 2016; 6:21; PMID:26870698; http://dx.doi.org/10.3389/fonc.2016.00021
- (2016) Front Oncol , vol.6 , pp. 21
- Bykov, V.J.N.¹ Zhang, Q.² Zhang, M.³ Ceder, S.⁴ Abrahmsen, L.⁵ Wiman, K.G.⁶

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.